JP5712207B2 - 脳疾患及び状態の予防及び治療のための組成物及び方法 - Google Patents
脳疾患及び状態の予防及び治療のための組成物及び方法 Download PDFInfo
- Publication number
- JP5712207B2 JP5712207B2 JP2012514552A JP2012514552A JP5712207B2 JP 5712207 B2 JP5712207 B2 JP 5712207B2 JP 2012514552 A JP2012514552 A JP 2012514552A JP 2012514552 A JP2012514552 A JP 2012514552A JP 5712207 B2 JP5712207 B2 JP 5712207B2
- Authority
- JP
- Japan
- Prior art keywords
- oegj
- extract
- brain
- disease
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims description 135
- 239000000203 mixture Substances 0.000 title description 47
- 238000000034 method Methods 0.000 title description 37
- 230000002265 prevention Effects 0.000 title description 19
- 208000014644 Brain disease Diseases 0.000 title 1
- 210000004556 brain Anatomy 0.000 claims description 119
- 239000000284 extract Substances 0.000 claims description 68
- 208000024827 Alzheimer disease Diseases 0.000 claims description 49
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 44
- 230000008929 regeneration Effects 0.000 claims description 38
- 238000011069 regeneration method Methods 0.000 claims description 38
- 208000018737 Parkinson disease Diseases 0.000 claims description 37
- 210000005036 nerve Anatomy 0.000 claims description 37
- 241000220259 Raphanus Species 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 29
- 230000000302 ischemic effect Effects 0.000 claims description 28
- 208000010877 cognitive disease Diseases 0.000 claims description 22
- 241000282414 Homo sapiens Species 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 201000006474 Brain Ischemia Diseases 0.000 claims description 13
- 206010008118 cerebral infarction Diseases 0.000 claims description 13
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 12
- 235000009709 Geum japonicum Nutrition 0.000 claims description 11
- 241001618015 Geum japonicum Species 0.000 claims description 11
- 230000008081 blood perfusion Effects 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 125000005233 alkylalcohol group Chemical group 0.000 claims description 6
- 230000003412 degenerative effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 230000033115 angiogenesis Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 206010061216 Infarction Diseases 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000007574 infarction Effects 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 description 86
- 239000003981 vehicle Substances 0.000 description 73
- 241000700159 Rattus Species 0.000 description 66
- 210000002569 neuron Anatomy 0.000 description 63
- 208000006011 Stroke Diseases 0.000 description 52
- 210000004204 blood vessel Anatomy 0.000 description 51
- 241001465754 Metazoa Species 0.000 description 50
- 230000003727 cerebral blood flow Effects 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 38
- 208000024891 symptom Diseases 0.000 description 37
- 229940079593 drug Drugs 0.000 description 35
- 230000000971 hippocampal effect Effects 0.000 description 34
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 32
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 32
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 32
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 32
- 210000001320 hippocampus Anatomy 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 210000001367 artery Anatomy 0.000 description 30
- 201000004810 Vascular dementia Diseases 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 208000032382 Ischaemic stroke Diseases 0.000 description 26
- 238000010171 animal model Methods 0.000 description 26
- 201000010099 disease Diseases 0.000 description 26
- 230000000694 effects Effects 0.000 description 24
- 230000012010 growth Effects 0.000 description 23
- 206010012289 Dementia Diseases 0.000 description 21
- 230000001976 improved effect Effects 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 21
- 210000005153 frontal cortex Anatomy 0.000 description 20
- 239000008187 granular material Substances 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 20
- 230000017531 blood circulation Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 230000036770 blood supply Effects 0.000 description 18
- 230000001684 chronic effect Effects 0.000 description 18
- 230000008449 language Effects 0.000 description 18
- 238000005259 measurement Methods 0.000 description 17
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 16
- 210000001652 frontal lobe Anatomy 0.000 description 16
- 230000001537 neural effect Effects 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 230000004069 differentiation Effects 0.000 description 15
- 210000003710 cerebral cortex Anatomy 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- 210000001947 dentate gyrus Anatomy 0.000 description 13
- 230000015654 memory Effects 0.000 description 13
- 210000001168 carotid artery common Anatomy 0.000 description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 230000013016 learning Effects 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 12
- 102000008730 Nestin Human genes 0.000 description 10
- 108010088225 Nestin Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 208000028867 ischemia Diseases 0.000 description 10
- 210000005055 nestin Anatomy 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000002604 ultrasonography Methods 0.000 description 10
- 230000002146 bilateral effect Effects 0.000 description 9
- 210000004958 brain cell Anatomy 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 208000028698 Cognitive impairment Diseases 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000002490 cerebral effect Effects 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 210000004129 prosencephalon Anatomy 0.000 description 8
- 238000012453 sprague-dawley rat model Methods 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 206010029113 Neovascularisation Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 7
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 230000003930 cognitive ability Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229960000187 tissue plasminogen activator Drugs 0.000 description 7
- 208000000044 Amnesia Diseases 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 206010044565 Tremor Diseases 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000001054 cortical effect Effects 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 229960003638 dopamine Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 230000009182 swimming Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 208000037259 Amyloid Plaque Diseases 0.000 description 5
- 102100021257 Beta-secretase 1 Human genes 0.000 description 5
- 206010065384 Cerebral hypoperfusion Diseases 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000007087 memory ability Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000031836 visual learning Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000036632 Brain mass Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 208000004547 Hallucinations Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- OXVUXGFZHDKYLS-BLIWDXROSA-N Tormentic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@](O)(C)[C@H]5C4=CC[C@@H]3[C@]21C OXVUXGFZHDKYLS-BLIWDXROSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 230000004031 neuronal differentiation Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000036581 peripheral resistance Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 210000003523 substantia nigra Anatomy 0.000 description 4
- 206010042772 syncope Diseases 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010048964 Carotid artery occlusion Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- -1 acyclic alkanes Chemical class 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 210000000877 corpus callosum Anatomy 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000000569 greater omentum Anatomy 0.000 description 3
- 230000001146 hypoxic effect Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000006984 memory degeneration Effects 0.000 description 3
- 208000023060 memory loss Diseases 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- VULLSLYDWNGNKZ-UHFFFAOYSA-N 12319Tetrahydroxyurs-12-en-28-oic acid Natural products OC1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C VULLSLYDWNGNKZ-UHFFFAOYSA-N 0.000 description 2
- HNRMPXKDFBEGFZ-UHFFFAOYSA-N 2,2-dimethylbutane Chemical compound CCC(C)(C)C HNRMPXKDFBEGFZ-UHFFFAOYSA-N 0.000 description 2
- 241001278836 Agrimonia pilosa Species 0.000 description 2
- 235000000641 Agrimonia pilosa Nutrition 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 206010069729 Collateral circulation Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010014498 Embolic stroke Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- OXVUXGFZHDKYLS-UHFFFAOYSA-N Jacarandic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)C(O)(C)C5C4=CCC3C21C OXVUXGFZHDKYLS-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 208000007542 Paresis Diseases 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 2
- 244000155437 Raphanus sativus var. niger Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010043647 Thrombotic Stroke Diseases 0.000 description 2
- 241001403962 Thymus mongolicus Species 0.000 description 2
- 235000017715 Thymus pulegioides Nutrition 0.000 description 2
- 240000006001 Thymus serpyllum Species 0.000 description 2
- 235000004054 Thymus serpyllum Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 230000008084 cerebral blood perfusion Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000008918 emotional behaviour Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 210000000020 growth cone Anatomy 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000003140 lateral ventricle Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000004973 motor coordination Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002640 oxygen therapy Methods 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000004810 partition chromatography Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008529 pathological progression Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 229940092385 radish extract Drugs 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- HFGSQOYIOKBQOW-PUNAAJGVSA-N (1S,2R,4aS,6aR,6aS,6bR,8aR,10R,12aR,14bS)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid Chemical compound C1C(O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C HFGSQOYIOKBQOW-PUNAAJGVSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MDZKJHQSJHYOHJ-KRGADYIYSA-N (4as,6ar,6as,6br,8ar,10r,11s,12ar,14bs)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1[C@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-KRGADYIYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710150192 Beta-secretase 1 Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710104127 CCAAT/enhancer-binding protein zeta Proteins 0.000 description 1
- 102100037676 CCAAT/enhancer-binding protein zeta Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000029812 Cerebral Small Vessel disease Diseases 0.000 description 1
- 241001124216 Cicindelinae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000005622 Gait Ataxia Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001327631 Meara Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000880595 Mus musculus CCAAT/enhancer-binding protein zeta Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- RZMHECYBKLOMKN-UHFFFAOYSA-N OC(=O)CP(=O)=O Chemical compound OC(=O)CP(=O)=O RZMHECYBKLOMKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000246358 Thymus Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 239000012072 active phase Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007657 cerebral ischemic lesion Effects 0.000 description 1
- 230000003788 cerebral perfusion Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004185 countercurrent chromatography Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930192479 gemin Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000008801 hippocampal function Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 208000022119 inability to concentrate Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000002747 omentum Anatomy 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000011631 stroke animal model Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Chemical class 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000005111 ventral hippocampus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18670909P | 2009-06-12 | 2009-06-12 | |
| US61/186,709 | 2009-06-12 | ||
| US18790509P | 2009-06-17 | 2009-06-17 | |
| US61/187,905 | 2009-06-17 | ||
| PCT/IB2010/001418 WO2010143063A1 (en) | 2009-06-12 | 2010-06-11 | Compositions and methods for prevention and treatment of brain diseases and conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012529487A JP2012529487A (ja) | 2012-11-22 |
| JP2012529487A5 JP2012529487A5 (enExample) | 2013-07-25 |
| JP5712207B2 true JP5712207B2 (ja) | 2015-05-07 |
Family
ID=43308481
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514552A Expired - Fee Related JP5712207B2 (ja) | 2009-06-12 | 2010-06-11 | 脳疾患及び状態の予防及び治療のための組成物及び方法 |
| JP2012514548A Expired - Fee Related JP5689117B2 (ja) | 2009-06-12 | 2010-06-11 | 心不全を防止及び治療するための組成物及び方法 |
| JP2012514550A Expired - Fee Related JP5892928B2 (ja) | 2009-06-12 | 2010-06-11 | 赤血球凝固の予防及び治療のための組成物並びに方法 |
| JP2012514554A Expired - Fee Related JP5892929B2 (ja) | 2009-06-12 | 2010-06-11 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
| JP2012514549A Expired - Fee Related JP6076737B2 (ja) | 2009-06-12 | 2010-06-11 | 高血圧症の防止及び治療のための組成物並びに方法 |
| JP2012514551A Expired - Fee Related JP5827618B2 (ja) | 2009-06-12 | 2010-06-11 | 冠動脈性心疾患の予防及び治療のための組成物及び方法 |
| JP2015111092A Pending JP2015155468A (ja) | 2009-06-12 | 2015-06-01 | 赤血球凝固の予防及び治療のための組成物並びに方法 |
| JP2015124801A Pending JP2015164963A (ja) | 2009-06-12 | 2015-06-22 | 冠動脈性心疾患の予防及び治療のための組成物及び方法 |
| JP2015126506A Expired - Fee Related JP6187831B2 (ja) | 2009-06-12 | 2015-06-24 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
| JP2015126332A Pending JP2015164966A (ja) | 2009-06-12 | 2015-06-24 | 高血圧症の防止及び治療のための組成物並びに方法 |
| JP2017090148A Withdrawn JP2017128608A (ja) | 2009-06-12 | 2017-04-28 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
Family Applications After (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012514548A Expired - Fee Related JP5689117B2 (ja) | 2009-06-12 | 2010-06-11 | 心不全を防止及び治療するための組成物及び方法 |
| JP2012514550A Expired - Fee Related JP5892928B2 (ja) | 2009-06-12 | 2010-06-11 | 赤血球凝固の予防及び治療のための組成物並びに方法 |
| JP2012514554A Expired - Fee Related JP5892929B2 (ja) | 2009-06-12 | 2010-06-11 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
| JP2012514549A Expired - Fee Related JP6076737B2 (ja) | 2009-06-12 | 2010-06-11 | 高血圧症の防止及び治療のための組成物並びに方法 |
| JP2012514551A Expired - Fee Related JP5827618B2 (ja) | 2009-06-12 | 2010-06-11 | 冠動脈性心疾患の予防及び治療のための組成物及び方法 |
| JP2015111092A Pending JP2015155468A (ja) | 2009-06-12 | 2015-06-01 | 赤血球凝固の予防及び治療のための組成物並びに方法 |
| JP2015124801A Pending JP2015164963A (ja) | 2009-06-12 | 2015-06-22 | 冠動脈性心疾患の予防及び治療のための組成物及び方法 |
| JP2015126506A Expired - Fee Related JP6187831B2 (ja) | 2009-06-12 | 2015-06-24 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
| JP2015126332A Pending JP2015164966A (ja) | 2009-06-12 | 2015-06-24 | 高血圧症の防止及び治療のための組成物並びに方法 |
| JP2017090148A Withdrawn JP2017128608A (ja) | 2009-06-12 | 2017-04-28 | 生存期間及び健康寿命を増加させるための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US9629884B2 (enExample) |
| EP (6) | EP2440212A4 (enExample) |
| JP (11) | JP5712207B2 (enExample) |
| CN (6) | CN102497873B (enExample) |
| AU (11) | AU2010258352B2 (enExample) |
| WO (6) | WO2010143063A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12397008B2 (en) * | 2006-04-13 | 2025-08-26 | Lead Billion Limited | Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries |
| JP5712207B2 (ja) | 2009-06-12 | 2015-05-07 | ジェネレックス ファーマシューティカルズ インコーポレイテッド | 脳疾患及び状態の予防及び治療のための組成物及び方法 |
| AU2011349207A1 (en) * | 2010-12-23 | 2013-07-11 | Huya Bioscience International Llc | Purified cardiogenin isomer and related methods |
| JP6000521B2 (ja) * | 2011-08-10 | 2016-09-28 | 株式会社ブルボン | 血圧上昇抑制剤 |
| ES2688879T3 (es) | 2012-05-16 | 2018-11-07 | Prairie Berry Europe Gmbh | Ácidos triterpénicos pentacíclicos polihidroxilados como inhibidores de la HMG-CoA reductasa |
| US20140044813A1 (en) * | 2012-08-09 | 2014-02-13 | Kemin Industries, Inc. | Plant Extracts for Improving Cognitive Health and Function |
| CN103623753B (zh) * | 2013-11-27 | 2016-03-23 | 大兴安岭嘉迪欧营养原料有限公司 | 大兴安岭野生金老梅总三萜提取物的制备方法 |
| CN106074560A (zh) * | 2013-11-29 | 2016-11-09 | 江西中医药大学 | 覆盆子提取物的应用 |
| US20150174057A1 (en) * | 2013-12-24 | 2015-06-25 | Generex Pharamaceutics Inc. | Compositions and methods for the prevention and treatment of oral diseases |
| KR20160113277A (ko) * | 2014-01-30 | 2016-09-28 | 케민 인더스트리즈, 인코포레이티드 | 인지 기능을 개선시키기 위한 식물 추출물 |
| CN105311030B (zh) * | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN104971091B (zh) * | 2015-06-03 | 2019-08-13 | 兴明生物医药技术(上海)有限公司 | 一种用于制备促进心肌再生药物的提取物的制备方法及其应用 |
| EP3325992B1 (en) | 2015-07-24 | 2026-01-28 | Northeastern University | Quantitative magnetic resonance imaging of the vasculature |
| EP3340992B1 (en) * | 2015-09-04 | 2022-12-28 | The Board of Regents of the University of Texas System | Method for treatment of monocyte dysfunction and chronic inflammatory micro-and macro-vascular diseases |
| CN105106222B (zh) * | 2015-09-14 | 2020-05-08 | 新乡医学院 | 吐曼酸在制备治疗或预防雌激素缺乏引起的阿尔茨海默病药物中的应用 |
| CN106581006B (zh) * | 2015-10-16 | 2019-11-29 | 香港理工大学深圳研究院 | 三萜类化合物在制备治疗帕金森药物中的应用 |
| CN106153761B (zh) * | 2016-06-07 | 2018-08-14 | 贵州师范大学 | 同时检测无籽刺梨果实中3种黄酮类成分的方法 |
| JP7361470B2 (ja) | 2016-06-20 | 2023-10-16 | バタフライ ネットワーク，インコーポレイテッド | ユーザによる超音波装置の操作を援助するための自動画像取得 |
| JP7207710B2 (ja) * | 2016-11-02 | 2023-01-18 | テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 血液の粘度を低減し、血液循環内の乱流を抑制し、連銭を治療するシステム及び方法 |
| WO2018200736A2 (en) * | 2017-04-25 | 2018-11-01 | The Buck Institute For Research On Aging | Formulations for extending lifespan and healthspan |
| CN106946971A (zh) * | 2017-04-28 | 2017-07-14 | 南宁馨艺荣生物科技有限公司 | 一种从积雪草中提取积雪草酸的工艺 |
| CN107445855B (zh) * | 2017-08-07 | 2018-12-14 | 绍兴市逸晨医疗科技有限公司 | 一种盐酸多西环素杂质c的制备方法 |
| WO2019172174A1 (ja) * | 2018-03-05 | 2019-09-12 | 日本新薬株式会社 | Ｒａｇｅシグナル阻害作用をもつ食品素材 |
| TW202000899A (zh) | 2018-03-06 | 2020-01-01 | 美商艾沛邦股份有限公司 | 可注射之即用軟骨、肌腱及韌帶修復組合物及使用方法 |
| US20210298662A1 (en) * | 2018-07-27 | 2021-09-30 | Northeastern University | Diagnosis of Dementia by Vascular Magnetic Resonance Imaging |
| KR102152182B1 (ko) * | 2018-09-05 | 2020-09-04 | 한국식품연구원 | 큰뱀무 추출물을 유효성분으로 함유하는 우울 증상 또는 스트레스의 개선, 예방 또는 치료용 조성물 |
| EP3856166A4 (en) | 2018-09-25 | 2022-06-22 | Ponce de Leon Health Designated Activity Company | METHOD FOR MAKING CALCIUM ALPHA-KETOGLUTARATE |
| WO2020124222A1 (en) | 2018-12-21 | 2020-06-25 | ARLANXEO Canada Inc. | Halogen recovery in a wet process for halogenating unsaturated isoolefin copolymer |
| CN109884222B (zh) * | 2019-01-17 | 2021-07-13 | 贵州中医药大学 | 一种小花清风藤的hplc指纹图谱建立方法 |
| KR102152174B1 (ko) * | 2020-03-30 | 2020-09-04 | 한국식품연구원 | 큰뱀무 추출물을 유효성분으로 함유하는 인지기능 장애의 개선, 예방 또는 치료용 조성물 |
| CN111643556A (zh) * | 2020-07-16 | 2020-09-11 | 杭州科倍安生物制药有限公司 | 一种用于预防和治疗痔疮的药物及其应用 |
| WO2022043407A1 (fr) | 2020-08-25 | 2022-03-03 | Laouarem Yousra | Compositions destinées au traitement des troubles neurologiques |
| KR102574207B1 (ko) * | 2020-12-03 | 2023-09-04 | 경북대학교 산학협력단 | 뱀무 추출물을 유효성분으로 하는 혈전성 질환 치료 또는 예방용 조성물 |
| CN112587599A (zh) * | 2021-01-11 | 2021-04-02 | 贵州中医药大学 | 一种预防急性高原反应的中药组合物 |
| CN112755079A (zh) * | 2021-01-18 | 2021-05-07 | 杭州科倍安生物制药有限公司 | 一种预防血栓形成或溶解已形成血栓的药物及其制备方法 |
| CN113367166B (zh) * | 2021-05-13 | 2022-07-26 | 海南大学 | 一种褐背蒲桃提取物杀菌剂及其制备方法和应用 |
| CN114028459A (zh) * | 2021-11-11 | 2022-02-11 | 杭州科贝生物制药有限公司 | 预防和治疗哺乳动物缺血性心脏病的药物和制备方法及应用 |
| CN114722066B (zh) * | 2022-03-23 | 2023-04-07 | 电子科技大学 | 一种预测材料自旋霍尔电导及反常霍尔电导的方法 |
| CN117257781A (zh) * | 2022-06-13 | 2023-12-22 | 上海市东方医院（同济大学附属东方医院） | 美金刚通过靶向心房心肌细胞谷氨酸受体有效干预房颤 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP2871763B2 (ja) * | 1989-12-15 | 1999-03-17 | 株式会社資生堂 | テストステロン―５α―レダクターゼ阻害剤 |
| CN1069629A (zh) | 1991-08-27 | 1993-03-10 | 段民生 | 一种康复面的制备方法 |
| CN1047089C (zh) * | 1992-12-03 | 1999-12-08 | 张斌 | 治疗近视眼的药物及制备工艺 |
| CN1102993A (zh) | 1993-12-21 | 1995-05-31 | 吴文才 | 多酶体系加工中草药的制剂方法 |
| JPH07179347A (ja) * | 1993-12-21 | 1995-07-18 | Showa Shell Sekiyu Kk | 抗ウイルス組成物 |
| US5589154A (en) | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| ATE359071T1 (de) | 1997-05-15 | 2007-05-15 | Univ Washington | Zusammensetzung und verfahren zur behandlung der alzheimer'schen krankheit und anderen amyloidosen |
| CN1176814A (zh) | 1997-06-26 | 1998-03-25 | 李静 | 预防和治疗脑血管病的口服液 |
| CN1102399C (zh) | 2000-06-09 | 2003-03-05 | 张庆玉 | 降脂通脉胶囊 |
| AU2001278341A1 (en) | 2000-07-26 | 2002-02-05 | Vitaplant Ag | Piper methysticum plant extract |
| WO2002009720A1 (en) | 2000-07-31 | 2002-02-07 | University Of Virginia Patent Foundation | Inhibitors of dna polymerase sigma |
| US6629835B2 (en) | 2000-08-01 | 2003-10-07 | Metaproteomics, Llc | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 |
| JP2002255804A (ja) | 2001-03-02 | 2002-09-11 | Suntory Ltd | インシュリン様作用を有するヘキサオキシジフェン酸誘導体を含んでなる組成物 |
| WO2002078685A1 (en) | 2001-03-30 | 2002-10-10 | The Nisshin_Oillio, Ltd. | Drugs for vascular lesion |
| KR100453569B1 (ko) * | 2001-09-11 | 2004-10-20 | 대한민국 | 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는항산화제 |
| JP2003201229A (ja) | 2001-10-23 | 2003-07-18 | Shiseido Co Ltd | マトリックスメタロプロテアーゼ活性阻害剤および抗老化用化粧料 |
| PT1446134E (pt) * | 2001-11-21 | 2010-12-17 | Univ Hong Kong Chinese | Composição compreendendo extractos orgânicos de geum japonicum thunb var. e sua utilização |
| JP4393777B2 (ja) | 2002-03-19 | 2010-01-06 | 株式会社ファンケル | 抗ヘリコバクター・ピロリ用組成物 |
| JP4498145B2 (ja) * | 2002-12-10 | 2010-07-07 | ザ・チャイニーズ・ユニバーシティー・オブ・ホンコン | ダイコンソウの有機抽出物を含む治療用組成物およびダイコンソウの有機抽出物の使用 |
| CN1239155C (zh) | 2003-01-23 | 2006-02-01 | 北京中医药大学 | 一种治疗缺血性脑中风的药物组合物及其制备方法 |
| US20040247698A1 (en) | 2003-06-04 | 2004-12-09 | Valenzuela Cortes Carmen Maria | Erectile Dysfunction Treatment |
| WO2005034958A1 (en) * | 2003-10-10 | 2005-04-21 | Sk Chemicals, Co., Ltd. | Triterpene compounds which are effective on improvement of brain function |
| CN1185007C (zh) | 2003-12-08 | 2005-01-19 | 张小朋 | 降脂溶栓药物 |
| CN100509008C (zh) | 2004-04-12 | 2009-07-08 | 赵晓昂 | 舒痛方及其制剂和用途 |
| WO2006054370A1 (en) | 2004-11-16 | 2006-05-26 | Use-Techno Corporation | Gluconeogenesis inhibiting agent |
| KR100704003B1 (ko) * | 2005-06-10 | 2007-04-06 | 안동대학교 산학협력단 | 2-알파-하이드록시-올레아놀산을 함유하는 트롬빈 저해혈전증 예방 및 치료용 조성물 |
| JP2006347967A (ja) | 2005-06-16 | 2006-12-28 | Yuusu Techno Corporation:Kk | 血糖値上昇抑制剤 |
| WO2007049088A1 (en) | 2005-10-27 | 2007-05-03 | Lead Billion Limited | Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues |
| WO2007049089A1 (en) | 2005-10-27 | 2007-05-03 | Lead Billion Limited | Method of stimulating growth of functional blood vessels and/or regeneration of myocardium in damaged tissues |
| EP1848440B1 (en) | 2005-10-27 | 2013-07-17 | Lead Billion Limited | Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries |
| KR100718602B1 (ko) | 2005-12-29 | 2007-06-21 | 대한민국 | 항비만 및 항염증 효과를 가지는 뱀무 추출물, 이를포함하는 식품 조성물 및 이들의 제조 방법 |
| JP2007204447A (ja) | 2006-02-03 | 2007-08-16 | Yoshihiro Futamura | 中性脂肪減少作用を呈するカルニチン誘導体、それからなる抗肥満薬、食品製剤及びセルライト減少作用を呈する化粧品 |
| JP4731350B2 (ja) | 2006-02-17 | 2011-07-20 | 丸善製薬株式会社 | 抗老化剤、皮膚化粧料及び美容用飲食品 |
| WO2007106049A1 (en) | 2006-03-16 | 2007-09-20 | Moleac Pte Ltd | Combination therapy for treatment of patients with neurological disorders and cerebral infarction |
| CN1857627B (zh) * | 2006-04-12 | 2010-05-19 | 贵阳利多药物技术开发有限公司 | 治疗中风的中药制剂及其制备方法 |
| US8821947B2 (en) | 2006-06-01 | 2014-09-02 | Howard W. Selby, III | Cholesterol-reducing diet |
| CN101091751A (zh) | 2006-06-22 | 2007-12-26 | 北京中医药大学 | 一种治疗高血压的中药组合物及其制备方法 |
| JP5281234B2 (ja) | 2006-06-27 | 2013-09-04 | ポーラ化成工業株式会社 | 毛様体過緊張による疲れ目の改善・予防のための経口投与組成物 |
| CN100528195C (zh) * | 2006-06-28 | 2009-08-19 | 海南晨菲药业有限公司 | 一种大青根注射剂制备工艺 |
| CN101099770A (zh) | 2006-07-04 | 2008-01-09 | 北京中医药大学 | 一种具有咪唑啉受体激动活性的药物组合物及制备方法和应用 |
| JP2008074801A (ja) | 2006-09-25 | 2008-04-03 | Oriza Yuka Kk | 肝保護剤 |
| JP5366358B2 (ja) * | 2006-09-29 | 2013-12-11 | 株式会社コーセー | 皮膚の老化機構に作用する剤、抗老化用皮膚外用剤、及び抗老化方法 |
| CN101040901A (zh) | 2007-04-12 | 2007-09-26 | 云南龙润药业有限公司 | 迷迭香提取物及其制备方法和应用 |
| US9205112B2 (en) | 2007-04-23 | 2015-12-08 | Creative Medical Health, Inc. | Combination treatment of cardiovascular disease |
| WO2008144706A2 (en) | 2007-05-21 | 2008-11-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Sweet gum fruit extract as a therapeutic agent |
| US20090022827A1 (en) | 2007-07-19 | 2009-01-22 | Ming Li | Agent and method for eliminating malignance of cancer cells without harmful effect to normal cells |
| CN101125171B (zh) | 2007-08-20 | 2010-05-26 | 刘凤元 | 一种男、女补强中药 |
| KR100891881B1 (ko) | 2007-08-23 | 2009-04-07 | 대한민국 | 3,4,5-트리히드록시벤즈알데히드를 유효성분으로 포함하는고지혈증 및 ｍｍｐ 과다활성으로 인한 혈관질환 예방 및치료용 조성물 |
| CN101406537B (zh) | 2007-10-11 | 2013-05-15 | 首都医科大学 | 柔毛水杨梅提取物用于制备治疗肥胖的药物的用途 |
| CN101274012B (zh) | 2008-01-23 | 2011-12-28 | 上海海天医药科技开发有限公司 | 夏枯草属植物提取物的组合物、制备方法及其药物用途 |
| JP5712207B2 (ja) | 2009-06-12 | 2015-05-07 | ジェネレックス ファーマシューティカルズ インコーポレイテッド | 脳疾患及び状態の予防及び治療のための組成物及び方法 |
-
2010
- 2010-06-11 JP JP2012514552A patent/JP5712207B2/ja not_active Expired - Fee Related
- 2010-06-11 WO PCT/IB2010/001418 patent/WO2010143063A1/en not_active Ceased
- 2010-06-11 US US13/377,501 patent/US9629884B2/en not_active Expired - Fee Related
- 2010-06-11 EP EP10785821A patent/EP2440212A4/en not_active Withdrawn
- 2010-06-11 AU AU2010258352A patent/AU2010258352B2/en not_active Ceased
- 2010-06-11 CN CN201080026127.0A patent/CN102497873B/zh not_active Expired - Fee Related
- 2010-06-11 AU AU2010258355A patent/AU2010258355B2/en not_active Ceased
- 2010-06-11 WO PCT/IB2010/001426 patent/WO2010143065A1/en not_active Ceased
- 2010-06-11 AU AU2010258356A patent/AU2010258356B2/en not_active Ceased
- 2010-06-11 JP JP2012514548A patent/JP5689117B2/ja not_active Expired - Fee Related
- 2010-06-11 EP EP10785820A patent/EP2440221A4/en not_active Withdrawn
- 2010-06-11 CN CN201080030503.3A patent/CN102548560B/zh not_active Expired - Fee Related
- 2010-06-11 US US13/377,503 patent/US20120077761A1/en not_active Abandoned
- 2010-06-11 EP EP10785819A patent/EP2440220A4/en not_active Withdrawn
- 2010-06-11 JP JP2012514550A patent/JP5892928B2/ja not_active Expired - Fee Related
- 2010-06-11 US US13/377,502 patent/US9950019B2/en active Active
- 2010-06-11 US US13/377,483 patent/US9050277B2/en not_active Expired - Fee Related
- 2010-06-11 AU AU2010258354A patent/AU2010258354B2/en not_active Ceased
- 2010-06-11 EP EP10785823A patent/EP2440223A4/en not_active Withdrawn
- 2010-06-11 EP EP10785818A patent/EP2440209A4/en not_active Withdrawn
- 2010-06-11 WO PCT/IB2010/001412 patent/WO2010143059A1/en not_active Ceased
- 2010-06-11 JP JP2012514554A patent/JP5892929B2/ja not_active Expired - Fee Related
- 2010-06-11 AU AU2010258358A patent/AU2010258358B2/en not_active Ceased
- 2010-06-11 CN CN201080030502.9A patent/CN102548571B/zh not_active Expired - Fee Related
- 2010-06-11 JP JP2012514549A patent/JP6076737B2/ja not_active Expired - Fee Related
- 2010-06-11 WO PCT/IB2010/001416 patent/WO2010143062A1/en not_active Ceased
- 2010-06-11 WO PCT/IB2010/001410 patent/WO2010143058A1/en not_active Ceased
- 2010-06-11 US US13/377,498 patent/US20120148691A1/en not_active Abandoned
- 2010-06-11 WO PCT/IB2010/001415 patent/WO2010143061A1/en not_active Ceased
- 2010-06-11 CN CN201080026128.5A patent/CN102573865B/zh not_active Expired - Fee Related
- 2010-06-11 EP EP10785822A patent/EP2440222A4/en not_active Withdrawn
- 2010-06-11 JP JP2012514551A patent/JP5827618B2/ja not_active Expired - Fee Related
- 2010-06-11 AU AU2010258351A patent/AU2010258351B2/en not_active Ceased
- 2010-06-11 CN CN201080026141.0A patent/CN102711768B/zh not_active Expired - Fee Related
- 2010-06-11 US US13/377,489 patent/US9283255B2/en not_active Expired - Fee Related
- 2010-06-11 CN CN201080026126.6A patent/CN102740870B/zh not_active Expired - Fee Related
-
2015
- 2015-06-01 JP JP2015111092A patent/JP2015155468A/ja active Pending
- 2015-06-22 JP JP2015124801A patent/JP2015164963A/ja active Pending
- 2015-06-24 JP JP2015126506A patent/JP6187831B2/ja not_active Expired - Fee Related
- 2015-06-24 JP JP2015126332A patent/JP2015164966A/ja active Pending
-
2016
- 2016-03-09 AU AU2016201525A patent/AU2016201525A1/en not_active Abandoned
- 2016-04-27 AU AU2016202674A patent/AU2016202674A1/en not_active Abandoned
-
2017
- 2017-04-10 US US15/482,894 patent/US20180055896A1/en not_active Abandoned
- 2017-04-19 AU AU2017202573A patent/AU2017202573B2/en not_active Expired - Fee Related
- 2017-04-19 AU AU2017202572A patent/AU2017202572B2/en not_active Expired - Fee Related
- 2017-04-28 JP JP2017090148A patent/JP2017128608A/ja not_active Withdrawn
-
2018
- 2018-03-29 AU AU2018202291A patent/AU2018202291A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5712207B2 (ja) | 脳疾患及び状態の予防及び治療のための組成物及び方法 | |
| Ghasemi et al. | Repeated intra-hippocampal injection of beta-amyloid 25–35 induces a reproducible impairment of learning and memory: considering caspase-3 and MAPKs activity | |
| TWI798320B (zh) | 神經系統疾患治療劑 | |
| Xiao et al. | Exercise-induced irisin ameliorates cognitive impairment following chronic cerebral hypoperfusion by suppressing neuroinflammation and hippocampal neuronal apoptosis | |
| US20240000853A1 (en) | Lipocalin-type prostaglandin d2 synthase production promoting agent | |
| CN107802621A (zh) | 青蒿素b抗神经炎症和治疗神经退行性疾病的用途 | |
| WO2018235016A1 (en) | A composition for treatment or prevention of a neurodegenerative disease | |
| US20200121753A1 (en) | Method for treating or alleviating autoimmune-related diseases | |
| US12441982B2 (en) | Pharmaceutical composition containing neprilysin-overexpressing stem cell, conditioned medium thereof, and exosome isolated therefrom as active ingredient for prevention or treatment of cognitive impairment | |
| US20120230986A1 (en) | Agent and Methods for Reducing Inflammatory Markers | |
| CN101361831B (zh) | 栀子苷在制备治疗血管性痴呆的药物中的用途 | |
| EP4035669A1 (en) | Preparation of drug for treating alzheimer's disease | |
| TWI544928B (zh) | 麥角固醇於製造藥劑之用途 | |
| RU2506950C2 (ru) | Комбинация карбостирила и карнитина | |
| EP4353234A1 (en) | Use of pyrrolopyrimidine compound | |
| US20230226124A1 (en) | Method for anti-ageing by using parabacteroides goldsteinii and its glycolipid | |
| Parra-Cid et al. | An enteric nervous system progenitor cell implant promotes a behavioral and neurochemical improvement in rats with a 6-OHDA-induced lesion | |
| US20230201134A1 (en) | Compositions for the management of demyelinating disorders | |
| US20110224300A1 (en) | USE OF POTASSIUM 2-(a- HYDROXYPENTYL) BENZOATE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTING AND/OR TREATING SENILE DEMENTIA | |
| US9636311B2 (en) | N,N′-di-1 naphthylguanidine HCl (NAGH) and N,N′-di-p-nitrophenylguanidine HCl (NAD) treatment for stroke at delayed timepoints | |
| CN121370926A (zh) | 一种治疗和/或预防抑郁症的药物组合物及其制备方法、应用 | |
| CN102805758B (zh) | 三两银总生物碱的新用途 | |
| CN103656485A (zh) | 一种治疗痴呆的中药组合物及其制备方法 | |
| CN103656484A (zh) | 一种中药组合物及其制备方法与应用 | |
| Xu et al. | Neuroprotectin D1 confers protection against epileptic rats by modulating neuroinflammation and autophagy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130607 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130607 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140528 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140827 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140929 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141006 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141014 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150302 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150309 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5712207 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |